Myocarditis Treatment Guidelines

Introduction to Myocarditis Management

• The American College of Cardiology recommends hospitalizing all patients with definite myocarditis at an advanced heart failure center and treating them with guideline-directed medical therapy for heart failure, while immunosuppression is generally not indicated except for specific subtypes like giant cell myocarditis, cardiac sarcoidosis, or eosinophilic myocarditis 1, 2

Immediate Hospitalization and Risk Stratification

• Hospitalize all patients with mild or moderate myocarditis at an advanced heart failure center, as recommended by the American College of Cardiology 3, 1
• Transfer patients with fulminant myocarditis to centers with expertise in mechanical circulatory support, according to the American College of Cardiology guidelines 3, 1, 2
• Fulminant myocarditis carries 28% mortality at 60 days despite aggressive treatment, but has better long-term prognosis than non-fulminant forms if patients survive the acute phase, as reported by the American College of Cardiology 2, 4

Standard Medical Therapy

• Initiate guideline-directed heart failure therapy before discharge and titrate in outpatient setting, as recommended by the American College of Cardiology and the American Heart Association 3, 5, 1, 2
• Use ACE inhibitors or ARBs for neurohormonal blockade, as recommended by the American College of Cardiology 2, 4
• Use beta-blockers for patients with supraventricular arrhythmias, but only if hemodynamically stable, according to the American College of Cardiology guidelines 1, 2, 4
• Use aldosterone antagonists for patients with mildly reduced left ventricular function and stable hemodynamics, as recommended by the American College of Cardiology 1

Mechanical Circulatory Support

• Initiate mechanical circulatory support urgently if shock does not reverse rapidly with pharmacological therapy, according to the American College of Cardiology guidelines 4
• Options include percutaneous cardiopulmonary support, ECMO, or intra-aortic balloon pump, as recommended by the American College of Cardiology 2, 4

Immunosuppression

• Consider immunosuppressive therapy in specific circumstances, such as giant cell myocarditis, cardiac sarcoidosis, or eosinophilic myocarditis, as recommended by the American College of Cardiology and the American Heart Association 5, 1, 2
• For immune checkpoint inhibitor-induced myocarditis, permanently discontinue the immunotherapy and start high-dose methylprednisolone, according to the American College of Cardiology guidelines 1, 2

Arrhythmia Management

• Acute arrhythmias often resolve with resolution of inflammation, and management is supportive, as reported by the American College of Cardiology 5
• Insert temporary pacemaker if symptomatic or high-grade AV block triggers ventricular tachyarrhythmias, according to the American College of Cardiology guidelines 4

Activity Restriction

• Mandate complete exercise abstinence for 3-6 months after diagnosis, as recommended by the American College of Cardiology and the American Heart Association 6, 5, 1
• Competitive sport participation should be avoided for 3-6 months, according to the American College of Cardiology guidelines 5, 1

Follow-Up Surveillance

• Perform follow-up testing 3-6 months after presentation to assess recovery, as recommended by the American College of Cardiology and the American Heart Association 1, 2
• Repeat echocardiography or cardiac MRI to assess ventricular function, and reassess cardiac biomarkers, according to the American College of Cardiology guidelines 2
• Dilated cardiomyopathy develops in 21% of patients during long-term follow-up, as reported by the American College of Cardiology 2

Immunosuppression in Myocarditis

Etiology-Specific Treatment

• The American College of Cardiology recommends immunosuppression with high-dose methylprednisolone 1000 mg/day IV followed by oral prednisone 1 mg/kg/day for immune checkpoint inhibitor-induced myocarditis, with a strength of evidence based on expert opinion 7
• For high-grade myocarditis with hemodynamic instability not responding to corticosteroids, the European Society of Cardiology suggests considering antithymocyte globulin, infliximab, mycophenolate mofetil, or abatacept, with a moderate strength of evidence based on observational studies 7, 8

Blood Pressure Monitoring and Management in Viral Myocarditis

Hospitalization and Continuous Hemodynamic Monitoring

• The American College of Cardiology recommends that all patients with confirmed viral myocarditis be admitted to an advanced heart‑failure center for continuous cardiac and hemodynamic monitoring, because early deterioration can occur even in mild‑to‑moderate cases. 9
• The Society advises immediate transfer to a facility capable of mechanical circulatory support (e.g., VA‑ECMO, percutaneous cardiopulmonary support, intra‑aortic balloon pump) when a patient presents with fulminant myocarditis characterized by cardiogenic shock, sustained ventricular arrhythmias, or high‑grade AV block. 9

Blood‑Pressure‑Guided Risk Stratification

• Lower admission systolic blood pressure is an independent prognostic marker; each 1 mmHg increase in systolic BP reduces the hazard of cardiac death or transplantation by approximately 4.3 %. Patients whose systolic BP falls below the cohort mean have a 2.8‑fold higher risk of adverse outcomes after adjustment for inflammation markers, NYHA class, and beta‑blocker use. 9

Guideline‑Directed Medical Therapy (GDMT) Initiation

• ACE‑inhibitors or ARBs should be started before discharge in every myocarditis patient with reduced left‑ventricular function to provide afterload reduction, maintain adequate blood pressure, and prevent adverse remodeling. 9
• Beta‑blockers are indicated only after confirming hemodynamic stability; they must be initiated at very low doses and titrated cautiously to avoid precipitating cardiogenic shock in patients with compromised ventricular function. 9

Adjunctive Pharmacologic Considerations

• Intravenous corticosteroids are recommended in three specific scenarios:

Follow‑Up Blood‑Pressure Surveillance and Therapy Adjustment

• A comprehensive cardiac reassessment should be performed at 3–6 months and include 12‑lead ECG, transthoracic echocardiography, 24–48 hour ambulatory rhythm monitoring, cardiac MRI, and a 10‑minute upright stress test to evaluate dynamic blood‑pressure and heart‑rate responses. 9
• Outpatient titration of guideline‑directed heart‑failure therapy must be guided by blood‑pressure tolerance and recovery of ventricular function, ensuring that patients remain hemodynamically stable before medication escalation. 9

Safety and Pitfall Avoidance

• Patients with low admission blood pressure must not be discharged until hemodynamic stability is confirmed, as low BP is a strong predictor of cardiac death or need for transplantation. 9
• Exercise should be avoided for 3–6 months after acute viral myocarditis; premature aerobic activity is associated with increased mortality and risk of sudden cardiac death. 9